Background {#Sec1}
==========

Acute brainstem syndrome (ABS) is an acute inflammatory demyelinating syndrome of the CNS that may occur in isolation or herald multiple sclerosis (MS), neuromyelitis optica (NMO), or recurrences of brainstem syndrome without other CNS manifestation (idiopathic recurrent brainstem encephalitis \[RBE\]) \[[@CR1]\]. Typical NMO is defined by attacks of myelitis and optic neuritis (ON) \[[@CR2]\]. The aquaporin 4 (AQP4)-specific serum autoantibody, NMO-IgG, is recognized as a specific biomarker for NMO \[[@CR3]\]. In NMO patients, ABS is untypical and not easily detected by physicians \[[@CR4]--[@CR7]\] and brainstem symptoms commonly presented as nausea, vomit, intractable hiccup \[[@CR8]--[@CR15]\], so ABS is easily neglected in NMO patients. In some cases of NMO, ABS acts as the first manifestation, which should be considered as a part of disease in addition to ON and myelitis \[[@CR4], [@CR12], [@CR13], [@CR16]\].

ABS is recognized more frequently in patients with NMO spectrum disorder (NMOSD), most brainstem symptoms exist even before the diagnosis of NMOSD \[[@CR10]--[@CR12], [@CR17]\]. In diagnostic criteria of NMOSD in 2015, ABS is considered as one of the core clinical characteristics in the diagnosis of NMOSD \[[@CR1]\]. In this study, the predictive value of anti-AQP4 antibody for relapse or later development was tested after the first sign of ABS.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Thirty-one patients with first-event ABS admitted to the Third Affiliated Hospital of Sun Yat-sen University in Guangzhou, China from January 2009 to September 2011 were retrospectively analyzed. All the patients involved in this study fulfilled the following inclusive criteria: 1) test for NMO-IgG; 2) single clinical episode of ABS associated with relevant brainstem MRI lesions 3) no other neurologic signs or symptoms which suggested the diagnosis of MS or NMO before NMO-IgG testing. Exclusion criteria included previous or concomitant systemic autoimmune diseases, metabolic etiology, vascular disorders and infections. All the patients were negative for HIV antibody.

The subjects provided written informed consent. This study was conducted according to the principles expressed in the Declaration of Helsinki and approved by the institution's ethics committee. Lumbar puncture was also performed with informed consent.

Data collection {#Sec4}
---------------

Clinical features and outcomes including gender, age at onset, duration, relapse times, annualized recurrence rate, clinical manifestations, and magnetic resonance imaging (MRI) findings were recorded in details. Analysis of cerebrospinal fluid (CSF), serum anti-AQP4 test and examinations of magnetic resonance imaging (MRI) were performed within 2 weeks after attack of brainstem symptoms and before treatment. The diagnosis of NMO, NMOSD and MS was based on Wingerchuk's criteria in 2006 \[[@CR18]\], International consensus diagnostic criteria for NMOSD in 2015 \[[@CR1]\] and McDonald's criteria in 2010 \[[@CR19]\] respectively. These symptoms, such as area postrema clinical syndrome (including intractable hiccups, nausea and vomiting), diplopia, and bulbar dysfunctions, were regarded as the manifestation of brainstem symptoms. A relapse of ABS was defined as definite brainstem symptoms of neurological dysfunction that lasted more than 24 h, together with relevant brainstem lesions after ruling out infective agents. Symptoms occurring within 1 month after the initial symptoms of relapse were considered to be part of the same episode. The neurological disability of the patients was assessed using the Kurtzke Expanded Disability Status Scale (EDSS) \[[@CR20]\]. A corticosteroid (1000 mg methyl prednisone, administered intravenously for five consecutive days) was prescribed in the acute stage and some patients received azathioprine in the remission stage when developed as NMO.

AQP4 and oligoclonal bands testing {#Sec5}
----------------------------------

AQP4 antibodies were determined using a cell-based assay on an AQP4-transfected cell line from a commercial BIOCHIP kit (EUROIMMUN AG, Lübeck, Germany) according to the manufacturer's instructions. The CSF oligoclonal bands (OCB) detection method used in our laboratory was an isoelectric focusing technique combined with the avidin-biotinperoxidase complex method.

MRI scanning {#Sec6}
------------

Brain and spinal cord MRI scans were carried out for all patients using a GE 1.5 T MR scanner (General Electric, Milwaukee, WI, USA). The slice thickness of the axial scans was between 3 and 5 mm. Conventional MRI protocols were used: T1 with and without gadolinium enhancement (400/15.5 ms, TR/TE) and T2 (2500--3500/100 ms, TR/TE) in spinal cord MRI; and T1 with and without gadolinium enhancement (2128--2300/11.6--12.4 ms, TR/TE), T2 (4600--4640/97.8--102 ms, TR/TE), and fluid-attenuated inversion recovery (FLAIR) (8800/120 ms, TR/TE) in brain MRI. A cross-sectional evaluation was also performed on all MRI scans of the brain, and brainstem lesions were classified as either having a ventral pattern, a dorsal pattern. The spinal cord was segmented into cervical and thoracolumbar regions. LETM is a spinal cord lesion that extends over 3 or more vertebral segments. All MRI scans were carried out prior to use of corticosteroid, immunomodulatory or immunosuppressive treatment. An experienced neuroradiologist and a neurologist, both of whom were blinded to the diagnostic categorization and the patients' clinical features, each analyzed all of the MRI scans. The final assessments were made by consensus.

Statistical analysis {#Sec7}
--------------------

All statistical analyses were performed using Statistical Program for Social Sciences (SPSS) statistical software (version 16.0; Chicago, IL, USA). For each set of values, data were expressed as the means ± standard deviation (SD). Categorical variables were compared using Fisher's exact test. Non-categorical variables were compared using the Mann-Whitney *U* test. Survival was estimated according to the Kaplan-Meier method. The primary study endpoint was the time to NMO conversion, as indicated by the Wingerchuk's criteria \[[@CR18]\]. The log-rank test was used to compare the survival analysis between anti-AQP4 (+) and anti-AQP4 (-) ABS patients. All *p*-values were two-tailed, with values of \< 0.05 considered significant. This study was an exploratory study so that no adjustment for multiple comparisons was made.

Results {#Sec8}
=======

The data of 352 patients in our database were reviewed between 2009 and 2011. A total of 31 patients who were enrolled in this study satisfied the diagnostic criteria: 14 anti-AQP4 (+) patients with ABS and 17 anti-AQP4 (-) patients with ABS. The details of the enrollment process can be seen in the flowchart (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Study flowchart

Clinical characteristics {#Sec9}
------------------------

In 31 ABS patients (female-male ratio is 5.2:1) 14 (45.16 %) were positive for anti-AQP4 antibodies (Table [1](#Tab1){ref-type="table"}). The mean age of onset for anti-AQP4 (+) ABS patients (31.21 ± 8.81 years) was similar to that of anti-AQP4 (-) patients (30.82 ± 8.55 years). According to Wingerchuk criteria in 2006, 71.43 % anti-AQP4 (+) patients (10/14) converted to NMO while only 11.76 % anti-AQP4 (-) ABS patients (2/17) converted to NMO within the follow-up after first-event brainstem symptoms (*p* \< 0.01). The 100 % anti-AQP4 (+) patients (14/14) converted to NMOSD while only 17.65 % anti-AQP4 (-) ABS patients (3/17) converted to NMOSD (*p* \< 0.001) according to International consensus diagnostic criteria for NMOSD in 2015. The cumulative NMO conversion probability was significantly higher in anti-AQP4 (+) patients than in anti-AQP4 (-) patients (Table [1](#Tab1){ref-type="table"}, OR 18.75; 95 % CI 2.871 to 122.452; *p* = 0.001).Table 1Comparison of clinical features between anti-AQP4 (+) and anti-AQP4 (-) patients with ABSClinical featuresAnti-AQP4 (+)\
*n* = 14Anti-AQP4 (-)\
*n* = 17Total\
*n* = 31*P* valueFemale/male ratio1:134:135:260.344Age of onset (±SD) (years)31.21 ± 8.8130.82 ± 8.5531.00 ± 8.520.902Duration of follow-up (months)46.35 ± 13.8040.00 ± 11.3044.51 ± 14.860.169Number of episodes3.71 ± 0.732.41 ± 1.543.00 ± 1.390.005Annual relapse rate1.05 ± 0.400.72 ± 0.400.87 ± 0.430.031NMOSD14/14 (100 %)3/17 (17.65 %)17/31 (54.84 %)\<0.001NMO10/14 (71.43 %)2/17 (11.76 %)12/31 (38.71 %)0.001MS0/14 (0.00 %)7/17 (41.17 %)7/31 (22.58 %)0.007Monophasic0/14 (0.00 %)7/17 (41.17 %)7/31 (22.58 %)0.007CSF examinations Total protein (mg/dl, ±SD)0.30 ± 0.100.25 ± 0.120.27 ± 0.110.204 Cell counts (number/μl, ±SD)11.29 ± 4.278.47 ± 2.079.74 ± 2.210.07 Pleocytosis \>50WBC/μl (%)2/140/172/310.196 IgG index0.68 ± 0.070.42 ± 0.130.54 ± 0.17\<0.01 Oligoclonal bands1/14 (7.14 %)1/17 (5.88 %)2/31 (6.45 %)0.708EDSS a3 (2--4)3 (2--3)3 (2--4)0.141EDSS b5 (3--7)2.5 (1.5--4.5)3.5 (1.5--7)\<0.001*ABS* acute brainstem syndrome, *NMO* neuromyelitis optica, *NMOSD* neuromyelitis optica spectrum disorder, *MS* multiple Sclerosis, *ON* optic neuritis, *CSF* cerebrospinal fluid, *EDSS* Kurtzke Expanded Disability Status Scale, a, EDSS scores at the first attack; b, EDSS scores of the last visit of follow-up

Brainstem symptoms {#Sec10}
------------------

The brainstem symptoms of 31 ABS patients were listed in Table [2](#Tab2){ref-type="table"}. Five anti-AQP4 (+) patients (35.71 %) experienced recurrent brainstem symptoms before the attacks of ON or myelitis, while only one anti-AQP4 (-) patients (5.88 %, *p* = 0.05) had more than one brainstem attacks. Area postrema clinical brainstem symptoms, such as hiccup (29.41 % vs 5.88 %, *p* = 0.05), nausea and vomiting (64.28 % vs 17.65 %, *p* = 0.011), occurred more frequently in anti-AQP4 (+) patients than those in anti-AQP4 (-) patients.Table 2Comparison of brainstem symptoms between anti-AQP4 (+) and anti-AQP4 (-) patients with ABSOnset symptomsAnti-AQP4 (+)Anti-AQP4 (-)Total*P* value*n* = 14*n* = 17*n* = 31Diplopia6/14 (42.86 %)8/17 (47.06 %)14/31 (45.16 %)0.551Area postrema clinical syndrome10/14 (71.43 %)3/17 (17.65 %)13/31 (41.94 %)0.004 Intractable hiccup5/14 (29.41 %)1/17 (5.88 %)6/31 (19.35 %)0.05 Nausea and vomiting9/14 (64.28 %)3/17 (17.65 %)12/31 (38.71 %)0.011Bulbar dysfunction5/14 (35.71 %)6/17 (35.29 %)11/31 (35.48 %)0.636 Dysarthria1/14 (7.14 %)3/17 (17.65 %)4/31 (12.90 %)0.378 Dysphagia2/14 (14.29 %)4/17 (23.53 %)6/31 (19.35 %)0.429 Alalia2/14 (14.29 %)0/17 (0 %)2/31 (6.45 %)0.196Vertigo4/14 (28.57 %)7/17 (41.18 %)11/31 (35.48 %)0.364Facial paralysis2/14 (14.29 %)5/17 (29.41 %)7/31 (22.58 %)0.287Ataxia3/14 (21.43 %)7/17 (41.18 %)7/31 (22.58 %)0.218Quadriplegia2/14 (14.29 %)1/17 (5.88 %)3/31 (9.68 %)0.425*ABS* acute brainstem syndrome

MRI examinations {#Sec11}
----------------

Brain and spinal cord MRI examinations were conducted for all patients. On the sagittal section of brain MRI, the lesions were more frequently occurred in the medulla of anti-AQP4 (+) patients than those in anti-AQP4 (-) patients (78.75 % vs 35.29 %, *p* = 0.019). However, there were no statistical differences in the other parts of brainstem between these two groups, such as midbrain and pons (Fig. [2](#Fig2){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). Dorsal-predominant lesions were involved more frequently in anti-AQP4 (+) patients than in the anti-AQP4 (-) patients (58.33 % vs 22.22 %, *p* = 0.01). The lesions in periependymal region were found more common in anti-AQP4 (+) patients than in anti-AQP4 (-) patients (35.29 % vs 7.14 %, *p* = 0.049) (Fig. [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). And the lesions in area postrema were found in 4 anti-AQP4 (+) patients and 3 anti-AQP4 (-) patients (28.57 % vs 17.64 %, *p* = 0.383) (Fig. [2](#Fig2){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). None of the spinal cord lesions were detected in the two groups when the initial episode of ABS. However, during the follow-up, segments of spinal cord lesions were longer in anti-AQP4 (+) patients than in anti-AQP4 (-) patients (5 vs 2, *p* = 0.001) (Table [4](#Tab4){ref-type="table"}). LETM were also found more commonly in anti-AQP4 (+) patients (64.29 % vs 17.65 %, *p* = 0.012) at the duration of follow-up (Table [4](#Tab4){ref-type="table"}).Fig. 2Axial T2-weighted (**a** and **b**; *arrow*) and sagittal T2 FLAIR (**c**; *arrow*) MRI show lesions occur in the medulla oblongata. Axial T2 FLAIR (**d** and **e**; *arrow*) MRI show pericanal lesions occur in the medulla oblongata. Linear faint Sagittal-T2-weighted high intensity signals are shown in the medulla oblongata (**f**; *arrow*) Table 3Comparison of brainstem MRI between anti-AQP4 (+) and anti-AQP4 (-) patients when the initial episode of ABSMRIsAnti-AQP4 (+)Anti-AQP4 (-)Total*P* value*n* = 14*n* = 17*n* = 31Brainstem lesionsSagittal view Pons6/14 (42.86 %)8/17 (47.06 %)14/31 (45.16 %)0.551 Midbrain3/14 (21.43 %)5/17 (29.41 %)8/31 (25.81 %)0.466 Medulla11/14 (78.57 %)6/17 (35.29 %)17/31 (54.84 %)0.019Axial view Dorsal11/14 (78.57 %)7/17 (41.17 %)18/31 (58.06 %)0.04 Ventral3/14 (21.43 %)10/17 (58.82 %)13/31 (41.94 %)0.04Periependymal region3/14 (21.43 %)1/17 (5.88 %)4/31 (12.90 %)0.228Area postrema4/14 (28.57 %)3/17 (17.64 %)7/31 (22.58 %)0.383*ABS* acute brainstem syndrome Fig. 3Axial T2-weighted FLAIR MRI shows periependymal lesions are involved in the dorsal midbrain (**a**, **b** and **f**, **g**; *arrow*) and pons (**c**, **d** and **h**, **i**; *arrows*). Sagittal T2-weighted FLAIR MRI shows increased signal surrounds the fourth ventricle (**e** and **j**; *arrows*) Table 4Comparison of brain and spinalcord MRI between anti-AQP4 (+) and anti-AQP4 (-) patients during follow-upMRIsAnti-AQP4 (+)Anti-AQP4 (-)Total*P* value*n* = 14*n* = 17*n* = 31Brain MRIsLesions in other brain regions Juxtacortical0/14 (0)2/17 (11.76 %)2/31 (6.45 %)0.488 Subcortical1/14 (7.14 %)5/17 (29.41 %)6/31 (19.35 %)0.185 Infratentorial14/14 (100 %)17/17 (100 %)31/31 (100 %)Spinal cord MRI Segments5 (3--7)2 (0--4)3.5 (0--8)0.001 Cervical10/14 (71.43 %)13/17 (76.47 %)23/31 (74.19 %)0.750 Thoracic7/14 (50 %)5/17 (29.41 %)12/31 (38.71 %)0.242 Cervical and thoracic3/14 (21.43 %)1/17 (5.88 %)4/31 (12.90 %)0.199 LETM9/14 (64.29 %)3/17 (17.65 %)12/31 (38.71 %)0.012Meet Barkhof criteria0/14 (0 %)5/17 (29.41 %)5/31 (16.13 %)0.185

CSF examinations {#Sec12}
----------------

CSF specimens were obtained from all patients at the acute stage (Table [1](#Tab1){ref-type="table"}). The protein concentrations in CSF of anti-AQP4 (+) patients (0.30 ± 0.10 mg/dl) were similar with those of anti-AQP4 (-) patients (0.25 ± 0.12 mg/dl). Anti-AQP4 (+) patients had a slightly higher number of white blood cells (WBCs) in CSF (11.29 ± 4.27) than anti-AQP4 (-) patients (8.47 ± 2.07). However, the values of IgG index in anti-AQP4 (+) patients were significantly higher than those of anti-AQP4 (-) patients (0.68 ± 0.07 vs 0.42 ± 0.13, *p* \< 0.01). Only one anti-AQP4 (+) ABS patient and one anti-AQP4 (-) ABS patient were positive for OCBs in CSF.

Prognosis in ABS patients {#Sec13}
-------------------------

All the patients were followed up at least 2 years after the first episode of ABS. The median duration of follow-up was 42 months (24--65 months). 7/31 (22.58 %) of patients did not show a second episode during the follow-up period, 12/31(38.70 %) of patients developed to NMO, 17/31(54.84 %) of patients converted to NMOSD, and 7/31(22.58 %) of patients converted to MS. In the follow-up duration, the mean annual relapse rates of anti-AQP4 (+) patients were significantly higher than those of anti-AQP4 (-) patients (1.05 ± 0.40 vs 0.72 ± 0.40, *p* = 0.031) (Table [1](#Tab1){ref-type="table"}). Although the EDSS scores at the first attack were similar between two groups, anti-AQP4 (+) patients presented a significantly higher EDSS scores than anti-AQP4 (-) patients at the last visit of follow-up \[5(3--7) VS 2.5(1.5--4.5), *p* \< 0.01\]. Kaplan-Meier survival analysis showed that the risk of developing to NMO in anti-AQP4 (+) patients were significantly higher than that in anti-AQP4 (-) patients (log rank 5.23, *p* = 0.012) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4A survival analysis comparison of the risk of developing to NMO between anti-AQP4 (+) (*n* = 14) and anti-AQP4 (-) (*n* = 17) patients with ABS (*p* = 0.012)

Discussion {#Sec14}
==========

NMO frequently begins with an acute or subacute episode of ON or myelitis. However, brainstem symptoms in NMO were not rare \[[@CR8], [@CR10]--[@CR12], [@CR17]\]. According to the previous studies, brainstem symptoms have recently been described in NMO as well as in NMOSD \[[@CR10], [@CR12], [@CR13], [@CR17], [@CR21]\]. In 17.05--30.61 % NMO patients, brainstem symptoms even act as the sole manifestation \[[@CR14], [@CR17]\]. "Brainstem symptoms with anti-AQP4 antibodies" has also been recommended in the latest diagnostic criteria for NMOSD \[[@CR1]\]. Various brainstem symptoms such as area postrema clinical brainstem symptoms (including intractable hiccups, nausea and vomiting), diplopia, and bulbar dysfunctions attributed to lesions in the dorsal region of the medullar and the pons surrounding the fourth ventricle could be the first manifestation of symptoms \[[@CR9], [@CR10], [@CR12], [@CR14]\]. Our results demonstrated that area postrema clinical brainstem symptoms in anti-AQP4 (+) ABS patients were more frequent than those in anti-AQP4 (-) ABS patients. Intractable hiccups, nausea, and vomiting have been reported as unique symptoms in NMO due to the involvement of the pericanal region in the medulla oblongata, which included the areas postrema, nucleus tractus solitaries where the putative hiccup and vomiting centres are located \[[@CR13], [@CR14]\]. In our study, intractable hiccups, nausea, and vomiting occur in 71.43 % anti-AQP4 (+) ABS patients, which are more frequent than in anti-AQP4(-) ABS patients. Previous study also confirmed that intractable hiccups, nausea, and vomiting are clinical markers for the early phase of an exacerbation in NMO \[[@CR22]\]. In addition, anti-AQP4 (+) ABS patients are prone to have recurrent brainstem symptoms before attacks of ON or myelitis.

In addition to clinical features, the distribution of brainstem lesions of anti-AQP4 (+) ABS patients also is different from anti-AQP4 (-) ABS patients. Although the midbrain and pons in the sagittal view are involved both in anti-AQP4 (+) ABS patients and anti-AQP4 (-) ABS patients, the medulla segments are more frequently involved in anti-AQP4 (+) ABS patients. In the axial view, anti-AQP4 (+) ABS patients present dorsal-predominant involvement, which is consistent with our previous report \[[@CR23]\]. In AQP4 (+) ABS patients, majority of the lesions (78.57 %) are observed in the medulla including 28.57 % lesions occurring in the area postrema. There is an agreement between MRI findings and clinical presentation of brainstem lesions. This study supports that the brainstem, especially medulla and area postrema, is the important region of attack in NMO \[[@CR11], [@CR17]\].

NMO-IgG has been proved to be highly specific and moderately sensitive to NMO. The prevalence of anti-AQP4 antibodies in NMO patients ranged from 50--60 % \[[@CR3], [@CR24]--[@CR26]\]. However, NMO-IgG is not restricted to these patients fulfilling all criteria for a definite diagnosis of NMO \[[@CR27]--[@CR29]\]. This antibody is also identified in partial syndromes, the frequency of anti-AQP4 in acute partial transverse myelitis is 4.5 % \[[@CR30]\], while 26.9 % in recurrent ATM \[[@CR31]\], increasing to 37.9--60 % in LETM \[[@CR27], [@CR31], [@CR32]\] and 20 % in recurrent ON \[[@CR33]\], 5.8 % in acute monosymptomatic ON \[[@CR34]\]. Our study provided that the frequency of anti-AQP4 in ABS is 45.16 %. Currently, sensitive marker(s) to predict the conversion of ABS to NMO are still absent. Our results found that 100 % of the anti-AQP4 (+) ABS patients experience clinical relapse, and 71.43 % of anti-AQP4 (+) ABS patients convert to NMO in the following 3 years, while only 11.76 % of the anti-AQP4 (-) ABS patients convert to NMO, and the cumulative NMO conversion probability is significantly higher in anti-AQP4 (+) ABS patients than that in anti-AQP4 (-) ABS patients. These results are similar to those patients with ON or LETM as the initial presentation, which also demonstrated a rapid NMO conversion in the first 2 years after the initial episode \[[@CR32], [@CR35]\]. The results suggested that anti-AQP4 antibodies may be useful for diagnosis and prognosis of patients who presented with isolated ABS. Moreover, 29.42 % of anti-AQP4 (+) ABS patients experience recurrent brainstem symptoms before attack of ON or myelitis, which suggested that anti-AQP4 antibody associated recurrent brainstem symptoms should be paid more attention. The anti-AQP4 (+) ABS patients are at high risk for development of severe disability.

Several studies have also identified a new antigenic target, myelin oligodendrocytic glycoprotein (MOG), as being of interest in seronegative AQP4 patients \[[@CR36]\]. Compared with AQP4-positivity patients, serum MOG antibodies do have a distinct clinical phenotype from AQP4-positivity NMO that is characterized by fewer relapses, a better clinical outcome, and a wider spectrum of MRI features, which may suggest a sort of disease distinct from NMO or MS \[[@CR37]--[@CR39]\]. This antibody is found in around 20 % of AQP4-seronegative patients. MOG testing was not performed in this study, therefore we can't exclude the bias of MOG-seropositive patients in our AQP4 negative cohort. However, brainstem lesions, which are a hallmark of AQP4-seropositive NMO/NMOSD, occur less frequently in MOG-seropositive patients \[[@CR38], [@CR40]\]. Moreover, the primary endpoint of our study is the conversion of typical NMO. Therefore, this would make little impact on our results.

Therapy of NMO should be initiated early. Azathioprine and rituximab are suggested as first-line treatments \[[@CR41]\]. In patients with NMOSD, IFN-β treatment \[[@CR42]\], glatiramer acetate \[[@CR43]\], natalizumab \[[@CR44]\] and fingolimod (FTY720) \[[@CR45]\] are ineffective for preventing relapses or fail to control disease activity. In our study, no patients received the above treatments, which might have treatment effects on accumulative NMO conversion probability. Therefore, the risk of conversion to NMO in anti-AQP4 (+) ABS patients seems higher in the first 2 years based on this study. We recommend that all patients with ABS make test for NMO-IgG and that seropositive patients receive immunosuppressive treatments which are effective in reducing NMO relapse frequency, such as azathioprine or rituximab.

Conclusions {#Sec15}
===========

ABS represents an inaugural or limited form of NMO in a high proportion of anti-AQP4 (+) patients.

ABS

:   Acute brainstem syndrome

AQP4

:   Aquaporin 4

CSF

:   Cerebrospinal fluid

EDSS

:   Expanded Disability Status Scale

MRI

:   Magnetic resonance imaging

NMO

:   Neuromyelitis optica

NMOSD

:   NMO spectrum disorder

OCB

:   Oligoclonal bands
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